Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-25-107666
Filing Date
2025-04-30
Accepted
2025-04-30 17:27:49
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d937270d10ka.htm   iXBRL 10-K/A 381877
2 EX-31.3 d937270dex313.htm EX-31.3 3438
3 EX-31.4 d937270dex314.htm EX-31.4 3377
  Complete submission text file 0001193125-25-107666.txt   755657

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rntx-20241231.xsd EX-101.SCH 5370
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rntx-20241231_def.xml EX-101.DEF 17617
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20241231_lab.xml EX-101.LAB 23338
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20241231_pre.xml EX-101.PRE 18751
20 EXTRACTED XBRL INSTANCE DOCUMENT d937270d10ka_htm.xml XML 12384
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38130 | Film No.: 25897668
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)